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and screening laboratory investigations. At Princess Margaret 
Hospital we perform bone marrow aspirates when screening stern 
cell donors. Bone marrow samples are examined for morphology 
and hemopoietic progenitor cell reserve using colony forming 
unit (CFU)-GEM~M assay. We report two potential donors with 
occult hematological malignancies on screening bone marrow 
aspirate. Neither patient had features of malignancy on history, 
physical examination or screening laboratory investigations. The 
first patient was a 65 year old man considered as donor for his 
brother with multiple myeloma. His past medical history and 
physical examination were unremarkable. Laboratory investiga- 
tions demonstrated a normal CBC and biochemistry. A bone 
marrow aspirate demonstrated the presence of 12 % atypical 
plasma cells. Fnrther investigations showed a monoclonal para- 
protein igG kappa of 19.6 g/1. Cytogenetic analysis was normal. 
This was most consistent with either monoclonal gammopathy of 
unknown significance or smoldering multiple myeloma. CFU- 
GEMM assay evaluation showed 144 CFU-C, 151 BFU-E, 12 
CFU-Meg and 4 CFU-GEMM. The second patient was a 72 
year old man whose brother had chronic lymphocytic leukemia 
(CLL)in Richters transformation. His past history and physical 
examination were unremarkable. Laboratory investigations 
demonstrated a normal CBC with a norma] lymphocyte count. 
Bone marrow aspiration showed increased cellularity with 50- 
60% small lymphocytes. A repeat bone marrow aspirate and 
biopsy confirmed these findings. Flow cytometry was consistent 
with CLL. CFU-GEMM assay showed 50 CFU-C, 43 BFU-E, 0 
CFU-Meg and 8 CFU-GEMM. Occult hematologic maligancies 
in these two donors were only demonstrated on bone marrow 
aspirates. CFU-GEMM assays showed decreased numbers of 
henmpoietic progenitors in both potential donors particularly in 
the patient with CLL. In conclusion, in views of the relatively 
innocuous nature of bone marrow aspiration we consider it advis 
able to screen particularly older stem cell donors with a bone 
marrow aspirate prior to donations. CFU-GEMM assays may 
contribute to the identification of bone marrow problems in 
potential donors. 
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PREDOMINANCE OF RESISTANT GRAM POSITIVE ISOLATES AS 
SOURCES OF BACTEREMIA IN GVHD PATIENTS TREATED WITH 
INFLIXIMAB 
Hk'ks, IC; Ippoliti, C.; Gh:alt, S.; De Lima, M.J.; Cohen1, A.; Dmmto, 
• i.; Kho~rri, L; Cl:ampliT~, R.; Coariel, D.R. Blood and3/la'Jv-ow T'lzalzs- 
pla,ztatiolz, UT MD A11de;solz Cm~cer CeJzter, Ho~t.rton, TX. 
lnfliximab has been evaluated as a treatment option for patients 
with GVHD due to its mechanism of tumor necrosis factor alpha 
blockade. We evaluated all bacteremic episodes that occurred 
within 6 months of infliximab administration i  31 patients with 
steroid-refi'actory acute GVHD between May 1999 and July 200 I. 
Patients were treated with 10 mg/kg of infliximab weekly for a 
median of 2 doses (range 1-12). All patients were receiving only 
steroids at the time of infliximab, and 17 (55%)required addtionaI 
salvage immunosuppressive agents. Each episode of bacteremia 
was defined by both clinical manifestations and microbiological 
docunaentation. Fourteen patients had a total of 21 bacteremic 
episodes, with a median time to infection of 84 days following the 
first dose of infliximab (range 2-177 days). Five episodes were 
caused by mu]tiple organisms (35%). Gram positive bacteria were 
isolated in I9(90%) bacteriemic episodes, and 3 (14%) of these 
involved nmltiple species. Gram negative bacteria were isolated in 
3 (14%) episodes. Gram negative isolates included Acinetobacter 
(n=l), Salmonella (n=l), Klebsiella pnemnonia (n= I), and Proteus 
vulgaris (n-l). Gram positive isolates included enterococci (n=l 1), 
staphylococci (n=7), streptococci (n=2) and diphtheroids (n=2). 
Specific enterococcal species isolated were E. faecimn (n=9), E. 
durans (n=l) and E. nmndii (n=l). All but one isolate (90%) were 
documented as vancomycin -resistant (VRE). Staphylococcal nd 
diphtheroid species also exhibited patterns of resistance; with 7/9 
isolates reporting sensitivity to only rifZampin or vancomycin. 6/14 
patients (43%) died during the study period, with half of these 
deaths (n=3) attributable to their bacteremia. These results sug- 
gest a high incidence of resistant gram positive bacteriemias in
patients with steroid-refractory acute GVHD treated with inflix- 
imab. Empiric antimicrobial regimens that include agents with 
coverage against hese types of resistant organisms hould be 
strongly considered when treating patients in this clinical setting. 
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CYTOMEGALOVIRUS (CMV) GASTROINTESTINAL DISEASE IN ALLO- 
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS 
UNDER PREEMPTIVE THERAPY BASED ON CMV ANTIGENEMIA OR 
POLYMERASE CHAIN REACTION 
MoJ'i, T.; Shimisu, T., Ai.% Y.; Nisbida, H., }~tma:.aki, R.; Ikeda, I"~; 
Okamoto, S. Keio Umversity School of 3/ledicil~e, To/eyo, Japing. 
Preemptive therapy for CMV infection/disease based on 
CMV antigenemia or polymerase chain reaction (PER) has 
been established as the standard approach fter al/ogeneic 
hematopoietic stem ceil transplantation (allo-HSCT). We have 
evaluated the failure cases developing CMV disease, particular- 
ly gastrointestinal (GI) disease, under CMV monitoring and 
the following preemptive therapy. [PATIENTS & METH-  
ODS] From February, 1996 to July, 2002, 172 patients 
received allo-HSCT in Keio University Hospital, and all were 
monitored CMV reactivation by CMV antigenemia (CI0/ l l )  
and plasma real-time PCR, whose positive results were fo]- 
lowed by preemptive therapy with ganciclovir. Among the 
patients, 12 patients developed histologically diagnosed CMV 
GI disease (upper and/or lower GI disease). All patients 
received allo HSCT (related 5, unrelated 7) for hematologic 
malignancies, including acute leukemia (n=6), myelodysplastic 
syndrome (n=3), chronic myelogenous leukemia (n=l), low- 
grade iympholna (n=l), and multiple myeloma (n=i). 10 
patients received TBI-based regimens, and 2 received fludara- 
bine-based regimen for conditioning. GVHD prophylaxis was 
short-term MTX with cyclosporin A (n=9) or with tacrolimus 
(n=3). All patients developed grades II-IV acute GVHD (grade 
II 9, grade 111 2, grade IV 1). [RESULTS] CMV GI disease 
developed at a median of day 31 post-transplant (range:19- 
120). CMV antingenemia and plasma real-time PCR did not 
became positive before the onset of CMV GI disease in 11 and 
8 of 12 patients, respectively. Throughout he clinical course, 
CMV antigenemia remained at a low level in 7 of 12 patients, 
while CMV copy number in plasma evaluated by real-time 
PCR markedly elevated in all patients. [CONCLUSION] Pre- 
emptive therapy based on CMV antigenemia or PeR allows 
the development of CMV GI disease, since CMV antigenemia 
and PCR does not precede the disease development or does not 
preceded early enough to prevent he disease development with 
anti-viral therapy. Furthermore, CMV antignemia could not 
reflect the activity of CMV GI disease, while plasma real time 
PCR could. 
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PHARMACOECONOMICS OF PROPHYLAXIS FOR FUNGAL INFEC- 
TIONS IN PATIENTS UNDERGOING A HEMATOPOIETIC STEM CELL 
TRANSPLANT 
To~g, K.B. o~ behalf of the HSCT Prophylaxis Ec'o]loT:zics Stady Grm~p, 
Sin1 Fram'isco, CA. 
BACKGROUND. A recent n, ulti-center, blinded, randomized, 
head-to-head comparative study evaluated the safety and efficacy 
of prophylaxis in 882 hematopoietie stem cell transplant (HSCT) 
patients using either micafungin or fluconazole. The overall suc- 
cess rate for micafungin was significantly higher than the rate for 
fluconazole patients (80.0% vs 73.5%). The incidence of systemic 
fimgal infections was lower for micafungin (1.6% vs 2.4%). The 
objective of this economic evaluation is to determine outcomes 
and costs associated with micafungin prophylaxis in HSCT con~! - 
pared to a no prophylaxis protocol. METHODS. A cost mini- 
mization study was performed to compare costs of no prophylaxis 
vs prophyla~s with micafungin. The analysis was conducted from 
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